PDCD1 and neoplasm: Generally believed, the efficacy of α-PD-1/PD-L1 is modest in EGFR-mutated patients [184, 185], which might be attributed to the lack of concurrent TIL and PD-L1 expression, low tumor mutation burden, or increased Tregs in the TME [186].